HROW

Harrow Inc

30.12

Nov 13 • 3:59 PM ET +1.82 (6.43%)

30.13

Aftermarket • 7:30 PM ET +0.01 (0.03%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Peers: BLCO ANIP TARS OCUL ALC OCS EYPT OTLK ALDX KPRX

| Held by: VTI IWM VXF FESM IWO XPH DFAS VTWO SCHA IHE

Scroll to Statements

Index	RUT
Market Cap	1.13B
Enterprise Value	1.36B
Income	-28.49M
Sales	303.25M
Book/sh	0.78
Cash/sh	2.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	373
IPO	Apr 24, 2007

P/E	-
Forward P/E	20.40
PEG	-
P/S	3.73
P/B	38.72
P/C	15.01
P/FCF	-
EV/EBITDA	54.69
EV/Sales	4.47
Quick Ratio	2.12
Current Ratio	2.29
Debt/Eq	10.31
LT Debt/Eq	10.28
Option/Short	Yes / Yes

EPS (ttm)	-0.77
EPS next Y	1.48
EPS next Q	0.61
EPS this Y	-157.94%
EPS next Y	508.92%
EPS next 5Y	-
EPS past 3/5Y	35.17% -1.53%
Sales past 3/5Y	45.39% 40.99%
EPS Y/Y TTM	-432.41%
Sales Y/Y TTM	21.28%
EPS Q/Q	866.41%
Sales Q/Q	38.61%
Earnings	Nov 09 AMC
EPS/Sales Surpr.	28.60% 0.71%

Insider Own	15.18%
Insider Trans	0.07%
Inst Own	59.17%
Inst Trans	3.96%
ROA	-7.07%
ROE	-74.77%
ROIC	-8.66%
Gross Margin	73.51%
Oper. Margin	0.80%
Profit Margin	-9.39%
SMA20	5.64%
SMA50	-2.12%
SMA200	-19.69%
Trades

Shs Outstand	37.52M
Shs Float	31.84M
Short Float	22.28%
Short Ratio	11.61
Short Interest	7.09M
52W High	54.85 -45.09%
52W Low	25.76 16.93%
Volatility	8.89% 5.74%
ATR (14)	1.84
RSI (14)	53.47
Beta	0.17
Rel Volume	1.21
Avg Volume	611.10K
Volume	736,480

Perf Week	12.01%
Perf Month	4.77%
Perf Quarter	-23.70%
Perf Half Y	-3.49%
Perf YTD	-38.53%
Perf Year	-20.51%
Perf 3Y	134.76%
Perf 5Y	171.84%
Perf 10Y	1032.33%
Recom	1.00
Target Price	63.11
Prev Close	28.30
Price	30.12
Change %	6.43%

Consensus

Strong Buy

Avg. Price Target

$63.11

Implied Upside

+109.5%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 09, 2026	Initiated	LLeerink Partners	Outperform	$45	+49.4%
Jul 11, 2025	Initiated	CCantor Fitzgerald	Overweight	$76	+152.3%
Jun 12, 2025	Initiated	BBTIG Research	Buy	$62	+105.8%
Jun 10, 2025	Initiated	WWilliam Blair	Outperform
Feb 06, 2025	Initiated	HH.C. Wainwright	Buy	$57	+89.2%
Dec 04, 2024	Reiterated	RB. Riley Securities	Buy	$73 → $69	+129.1%
Apr 11, 2024	Initiated	CCraig Hallum	Buy	$24	-20.3%
Sep 08, 2022	Resumed	RB. Riley Securities	Buy	$17	-43.6%
Oct 14, 2021	Resumed	RB. Riley Securities	Buy	$16	-46.9%
Sep 24, 2021	Initiated	AAegis Capital	Buy	$15	-50.2%
Jul 02, 2021	Initiated	LLadenburg Thalmann	Buy	$14.25	-52.7%

Nov-12-26 07:00AM	Harrow to Participate in Two Investor Conferences in November (GlobeNewswire)
Nov-10-26 10:46AM	Harrow's Record Quarter Is Overshadowed By A Halved EBITDA Outlook And A Steep Q4 Revenue Hurdle (Earnings Whispers) +10.52%
Nov-09-26 04:33PM	Harrow: Q3 Earnings Snapshot (Associated Press)
04:02PM	Harrow Announces Third Quarter 2026 Financial Results (GlobeNewswire)
Nov-02-26 07:35PM	Harrow Needs A Big Third-Quarter Jump To Keep Its Back-Half Revenue Promise Credible (Earnings Whispers)
09:00AM	Loading…
09:00AM	PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrows Eye Care Portfolio (Business Wire)
07:00AM	Harrow Launches HarrowRx Platform (GlobeNewswire)
Oct-26-26 07:00AM	Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 (GlobeNewswire)
Oct-05-26 07:00AM	Harrow Closes Acquisition of TYRVAYA (GlobeNewswire)
Sep-30-26 07:00AM	Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO (GlobeNewswire)
Sep-01-26 07:00AM	Harrow to Participate in Three Investor Conferences in September (GlobeNewswire)
Aug-20-26 07:00AM	Harrow Announces IHEEZO Data in Patient-Reported Discomfort Following Intravitreal Injections (GlobeNewswire)
Aug-11-26 03:01PM	Harrow Inc (HROW) (Q2 2026) Earnings Call Highlights: Record Demand and Strategic Expansion ... (GuruFocus.com)
Aug-10-26 05:50PM	Harrow: Q2 Earnings Snapshot (Associated Press)
04:05PM	Harrow Announces Second Quarter 2026 Financial Results (GlobeNewswire)
07:00AM	Loading…
Aug-06-26 07:00AM	Harrow Acquires Global Rights to TYRVAYA, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease (GlobeNewswire)
Jul-27-26 07:00AM	Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026 (GlobeNewswire)
Jul-20-26 08:00AM	Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ / AMELIVU), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026 (GlobeNewswire)
07:00AM	Harrow Highlights Growing Clinical Evidence Supporting IHEEZO and BYOOVIZ at ASRS 2026 Annual Meeting (GlobeNewswire)
Jul-01-26 07:00AM	Samsung Bioepis Relaunches BYOOVIZ (ranibizumab-nuna) in the United States in Partnership with Harrow (Business Wire)
07:00AM	Harrow Announces Commercial Launch of BYOOVIZ in the United States (GlobeNewswire)
Jun-10-26 07:00AM	Harrow Re-Launches VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare (GlobeNewswire) +7.29%
May-27-26 07:00AM	Harrow to Present at William Blair's 46th Annual Growth Stock Conference (GlobeNewswire)
May-12-26 03:01PM	Harrow Inc (HROW) Q1 2026 Earnings Call Highlights: Strong Product Demand Amid Revenue Challenges (GuruFocus.com) -23.69%
May-11-26 04:37PM	Harrow: Q1 Earnings Snapshot (Associated Press)
04:05PM	Harrow Announces First Quarter 2026 Financial Results (GlobeNewswire)
Apr-27-26 07:00AM	Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026 (GlobeNewswire)
Apr-16-26 07:00AM	Harrow Announces the Issuance of J-Code for IOPIDINE 1% (GlobeNewswire)
Apr-14-26 10:30AM	LogiCare3PL Selected as Distribution Partner by Harrow (PR Newswire)
Mar-24-26 04:57PM	Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030 (GlobeNewswire)
08:15AM	Loading…
08:15AM	Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth (GlobeNewswire)
Mar-18-26 07:00AM	Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting (GlobeNewswire)
Mar-09-26 09:03PM	Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions (GuruFocus.com)
Mar-04-26 07:00AM	Harrow to Present at Leerink Partner's 2026 Global Healthcare Conference (GlobeNewswire)
Mar-03-26 04:14PM	Why Harrow, An IBD 50 Stock Up 32% Since January, Just Crashed (Investor's Business Daily) -27.96%
11:18AM	Harrow Q4 Earnings Call Highlights (MarketBeat)
08:11AM	Why Is Eye-Disease-Focused Harrow Stock Falling Today? (Benzinga)
07:00AM	Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication (GlobeNewswire)
Mar-02-26 06:00PM	Harrow (HROW) Misses Q4 Earnings Estimates (Zacks)
05:08PM	Harrow: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance (GlobeNewswire)
Feb-28-26 09:32AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Feb-27-26 12:58PM	These Growth Stocks Form Classic Cup Bases. Here's Where To Buy. (Investor's Business Daily)
Feb-26-26 05:35AM	TheStreet Pro: Four Stocks that Will Win Despite Irrational Panic over AI (TipRanks)
Feb-24-26 10:00AM	Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? (Zacks)
08:00AM	Analysts Boost Profit Forecasts On Two Names. One Is A Data Center Play. (Investor's Business Daily)
Feb-23-26 02:20PM	Why IBD Stock Of The Day Harrow Has Its Sights On A Breakout (Investor's Business Daily)
10:00AM	Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-18-26 07:00AM	Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 (GlobeNewswire)
Feb-17-26 06:01PM	Private Capital's Strategic Moves: ECN Capital Corp Exit Impacts Portfolio by -3.57% (GuruFocus.com) +5.98%
07:00AM	Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack Kits (GlobeNewswire)
Feb-04-26 01:07PM	Eye Care Stock Sees New Path After Guidance (Investor's Business Daily)
Feb-03-26 06:28AM	Strength Seen in Harrow (HROW): Can Its 9.7% Jump Turn into More Strength? (Zacks) +5.10%
Feb-02-26 07:00AM	Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270-$280 Million, Marking Another Year of Strong Growth (GlobeNewswire) +9.67%
Jan-15-26 01:00PM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
08:55AM	Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength (Zacks)
Dec-09-25 12:56PM	Eye Drops Maker Sets Up After Strategic Buy; Sales Outlook Strong (Investor's Business Daily)
Nov-24-25 07:00AM	Harrow to Present at Two Investor Conferences in December (GlobeNewswire)
Nov-18-25 07:00AM	Harrow Announces Closing of Acquisition of Melt Pharmaceuticals (GlobeNewswire)
Nov-14-25 05:03PM	Private Capital's Strategic Moves: Spotlight on Matthews International Corp (GuruFocus.com) +7.65%
Nov-11-25 02:01PM	Harrow Inc (HROW) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth Plans (GuruFocus.com) +13.47%
Nov-10-25 04:31PM	Harrow: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Harrow Announces Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-27-25 07:00AM	Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 (GlobeNewswire)
Oct-08-25 11:23AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey) -5.14%
Oct-06-25 07:00AM	ImprimisRx Announces Leadership Changes (GlobeNewswire) -7.20%
Sep-26-25 08:57AM	Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? (Benzinga)
07:00AM	Harrow to Acquire Melt Pharmaceuticals (GlobeNewswire)
Sep-25-25 04:05PM	Harrow Launches Harrow Access for All (HAFA) (GlobeNewswire)
Sep-15-25 07:00AM	Harrow Announces Agenda and Speakers for Investor & Analyst Day (GlobeNewswire) +8.63%
Sep-08-25 05:57PM	Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 (GlobeNewswire) +7.52%
08:00AM	Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 (GlobeNewswire)
Sep-02-25 04:07AM	Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea (Insider Monkey)
Aug-26-25 04:15AM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Aug-15-25 12:20PM	Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock (Zacks)
10:00AM	Best Momentum Stock to Buy for August 15th (Zacks)
09:55AM	Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet (Zacks)
Aug-14-25 02:36PM	Harrow Stock Eyes Relative Strength Rating Upgrade (Investor's Business Daily) +9.62%
Aug-11-25 05:55PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second-Quarter 2025 Financial Results (GlobeNewswire)
09:23AM	Harrow Inc (HROW) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Aug-08-25 09:22AM	Harrow Inc (HROW) Q2 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
Aug-06-25 07:00AM	Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference (GlobeNewswire)
Aug-04-25 10:00AM	Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) +7.01%
Jul-29-25 07:00AM	Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025 (GlobeNewswire)
Jul-21-25 03:34PM	Harrow, Inc. (HROW): A Bull Case Theory (Insider Monkey)
Jul-17-25 07:00AM	Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
07:00AM	Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States (Business Wire)
Jul-14-25 10:01AM	Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? (Zacks)
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly) +11.35%
Jul-06-25 04:15AM	William Blair Initiates Coverage of Harrow (HROW) With an Outperform Rating (Insider Monkey)
Jul-02-25 09:00AM	Are Options Traders Betting on a Big Move in Harrow Stock? (Zacks)
Jun-18-25 07:00AM	Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications (Business Wire)
Jun-09-25 07:00AM	Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals (Business Wire)
May-14-25 10:07AM	Jim Cramer on Harrow, Inc. (HROW) - "Eye Care's a Good Biz - If It Makes Money, Don't Walk Away Pre-Breakout" (Insider Monkey)
07:00AM	Harrow to Present at Two Investor Conferences in May (Business Wire)
May-10-25 03:03AM	Harrow Inc (HROW) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
May-08-25 05:10PM	Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Harrow Announces First-Quarter 2025 Financial Results (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AMIR SHOJAEI	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Proposed Sale	40.00	11,250	450,000		Aug 21 06:32 PM
Shojaei Amir	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Option Exercise	35.96	11,250	404,550	11,250	Aug 17 05:47 PM
Shojaei Amir	CHIEF SCIENTIFIC OFFICER	Aug 14 '26	Sale	40.00	11,250	450,000	0	Aug 17 05:47 PM
Graves Adrienne L	Director	May 18 '26	Buy	31.07	1,000	31,070	1,000	May 19 07:00 AM
SILVERNAIL LAUREN P	Director	May 18 '26	Buy	31.00	1,000	31,000	1,000	May 19 07:00 AM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	May 14 '26	Buy	30.20	10,000	302,000	2,996,130	May 15 07:01 AM
BOLL ANDREW R.	PRESIDENT AND CFO	May 14 '26	Buy	29.90	3,500	104,650	814,679	May 15 07:00 AM
Opaleye Management Inc.	10% Owner	Mar 04 '26	Sale	39.67	138,263	5,485,184	59,428	Mar 05 04:05 PM
Opaleye Management Inc.	10% Owner	Mar 03 '26	Sale	39.15	60,309	2,361,242	63,691	Mar 05 04:05 PM
Opaleye Management Inc.	10% Owner	Feb 27 '26	Sale	54.18	5,000	270,900	65,000	Mar 03 04:05 PM
Opaleye Management Inc.	10% Owner	Jan 06 '26	Sale	53.35	20,000	1,066,914	70,000	Jan 08 04:05 PM
BOLL ANDREW R.	PRESIDENT AND CFO	Dec 12 '25	Option Exercise	3.95	60,000	237,000	837,844	Dec 16 08:50 PM
BAUM MARK L	CHIEF EXECUTIVE OFFICER	Dec 12 '25	Option Exercise	3.95	180,000	711,000	3,066,124	Dec 16 08:48 PM

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company's FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company's ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

CEOMr. Mark L. Baum J.D.

C.M.A.Mr. Andrew R. Boll C.F.A.

Pharm.D.Dr. Amir W. Shojaei Ph.D.

President & CEO of Harrow's ImprimisRx DivisionMr. Francis W. Mullery

Vice President of Investor Relations & CommunicationsMr. Michael D. Biega

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

HROW

Harrow Inc

Upgrade your Finviz experience

All the Features.
Half the Price.